trial · primary record
Opevesostat
Prostate Cancer Metastatic
| Phase | Phase 3 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 1310 |
| Primary completion | 2030-02-15 |
| Primary endpoint | Overall Survival (OS) in Androgen Receptor Ligand Binding Domain (AR LBD) Mutation-Positive Participants |
| Registry ID | NCT06136624 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-04T03:54:49.504Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT06136624
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.